international s.a.debiopharm research & manufacturing s.a.debiopharm investment s.a.debiopharm diagnostics s.a.genepoc inc.scientific awards & grantsdebiopharm academyentrepreneurshipsocial responsibility contact centerour headquarter is located in lausanne switzerland.phone 41 0 21 321 0111 to find the numbers of all the debiopharm group s companies use this page.businessbusiness modelpartneringpipelinetranslational medicinedrug discovery & preclinicalclinical developmentinnovative drug delivery and formulationmanufacturing & quality assuranceregulatory product pipelinemore infoproductseloxatin elplat dacotin dacplat oxaliplatin is a diaminocyclohexane dach platin for the treatment of colorectal cancer.decapeptyl trelstar pamorelin neo decapeptyl 1 to 6 month formulation for the treatment of prostate cancer of endometriosis precocious puberty uterine fibroids ovarian cancer breast cancer female infertility.salvacyl moapar for the treatment of severe sexual deviations . we develop for patientsmore infoscareers jobsdirector head of pharmacovigilancelausanne 16 august 2016research associate r & d analytiquemartigny 03 august 2016stagiaire charg e de missionlausanne 18 july 2016 see all jobs spontaneous application working at debiopharmapproximately 350 people of more than 18 nationalities from europe north and south america africa and asia are employed at debiopharm group on its sites.more infomediacorporate profilepress releaseseventscontact media relationspublicationslogo & media download areavideos latest newsthe japanese cancer association and debiopharm group announce winners of the 2016 jca mauvernay awarddebiopharm group 07 october 2016 all news debiopharm tv add this to your social network let s meetid week 2016october 26 30 2016all events follow ourproduct pipelinedebiopharmin 90 seconds all newsinternationallocalpublications07 october 2016 internationalthe japanese cancer association and debiopharm group announce winners of the 2016 jca mauvernay award read more 30 august 2016 internationaldebiopharm invests double digit millions in the canadian startup genepoc specialized in the development of rapid diagnostic tests read more 13 july 2016 internationaldebiopharm acquires a majority holding in the canadian start up genepoc read more all news02 june 2016fda grants orphan drug designation to debiopharm international sa s iap inhibitor debio 1143 in the treatment of ovarian cancer read more 15 april 2016debiopharm international sa announces presentation at aacr of non clinical data relating to its targeted investigational compound debio 1347 ch5183284 a selective fgfr 1 2 3 inhibitor read more 08 april 2016debiopharm international sa to present the latest findings on debio 1450 at eccmid read more all news18 december 2014debiopharm investment ardian nixdorf foundation and bernis today acquire eco delta solar activities read more 27 november 2014debiopharm investment becomes a minority shareholder in haut lac international bilingual school in st l gier vd read more 17 november 2014coorpacademy tabli l epfl et l un des leaders des moocs destination des entreprises l ve 3 2 millions d euros aupr s de debiopharm investment et du fonds fran ais nextstage read more all news21 june 2016population pharmacokinetic analysis of the iaps antagonist debio 1143 and its major metabolite in oncologic patients read more 30 april 2016phase 1 study of debio 1143 with concurrent chemo radiotherapy in locally advanced squamous cell carcinoma of the head and neck y. read more 21 april 2016fgfr selective inhibitor debio1347 induces tumor regressions in fgfr2 altered gastric cancer pdx models read more all news debiopharm group presented at a glance follow ourproduct pipeline discoverdebiopharm tv social & corporateresponsibility 2016 debiopharm group legal noticeterms & conditionscsonlinecreditssitemap previousnext